Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 9/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | FAP | Q12884 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL418202 | 0.81 | DRD4 (0.51) | DRD4ACEDPP8DPP9DPP4 | |
| SCHEMBL23537246 | 0.80 | DRD4 (0.50) | DRD4ACEDPP8DPP9DPP4 | |
| SCHEMBL26818008 | 0.77 | OPRM1 (0.55) | ACENAMPT | |
| SCHEMBL29854102 | 0.77 | DRD4 (0.48) | DRD4ACEDPP8DPP9DPP4 | |
| SCHEMBL18711185 | 0.75 | DRD4 (0.46) | DRD4ACEDPP8DPP9DPP4 | |
| SCHEMBL8222337 | 0.74 | DRD4 (0.48) | DRD4DRD1ABHD6NAMPT | |
| SCHEMBL29074413 | 0.73 | SLC6A2 (0.45) | DRD4ACEDPP8DPP9DPP4 | |
| SCHEMBL9508172 | 0.73 | DRD1 (0.57) | DRD4ACEDRD1 | |
| SCHEMBL14985698 | 0.72 | DRD4 (0.45) | DRD4ACELMNASMN1; SMN2 | |
| SCHEMBL12921565 | 0.72 | DRD4 (0.45) | DRD4ACELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064034-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064034-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | DRD4 4726/4885ACE 109/4885DPP8 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.